AUSTIN, TX, July 30, 2015 – Genprex, Inc. announced today that Jack A. Roth, MD FACS, Chairman of the Genprex Scientific and Medical Advisory Board, has been selected as the 2015 Honorary Member of The American Society for Radiation Oncology (ASTRO). Dr. Roth, recognized as a leading surgeon and distinguished cancer researcher, received the highest honor ASTRO bestowed to scientists and leaders in disciplines other than radiation oncology, radiobiology, or radiation physics. The induction as the 2015 ASTRO Honorary Member will be held at ASTRO’s 57th Annual Meeting at the Henry B. Gonzalez Center in San Antonio, Texas.
Dr. Roth joins an elite and distinguished list of notable scientific researchers. First awarded in 1989, ASTRO has only awarded Honorary Membership to 32 recipients. Dr. Roth’s research has received numerous grants and awards, including an NCI SPORE Grant in lung cancer. He has published more than 560 articles in peer-reviewed journals and 116 book chapters, and has 59 issued and 22 pending U.S. and foreign patients.
“Throughout his renowned career, Dr. Roth has demonstrated leadership and commitment to multidisciplinary approaches for treating lung cancer,” said Bruce G. Haffty, MD, FASTRO, chair of ASTRO’s Board of Directors. “Patients should benefit from his pivotal work comparing the use of stereotactic ablative radiation therapy [SABR] versus surgery for operable clinical stage I non-small cell lung cancer [NSCLC]. He and colleagues found that SABR may improve outcomes for stage I NSCLC patients compared to standard lobectomy in their study. Dr. Roth is an excellent surgeon and clinician, as well as an inspiring mentor. ASTRO thanks him for his outstanding achievements.”
“Cancer is a disease of dysfunctional genes,” Dr. Roth said. “A direct way to address this is to correct the genetic abnormalities through gene transfer. The first tumor suppressor gene therapy patient was treated by our group in 1995. This has been a long journey as well, with many technical challenges. However, during the past 5 years, real progress has been made in systemic gene delivery.”
Dr. Roth’s research and expertise extends beyond the lab where he has been responsible for training the next generation of surgical oncologists and laboratory researchers. “I hope this research will inspire physicians of all oncologic disciplines to work together to improve outcomes for cancer patients with the understanding that the best way to achieve this is through rigorous scientific investigation,” he said. “It is always a great feeling to be recognized by your peers,” Dr. Roth concluded. “My first thought was that this is a tribute to all the outstanding colleagues that I have been privileged to work with over the years.”
Dr. Roth is professor, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, MD Anderson Cancer Center, Houston, and chief, Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, Division of Surgery, MD Anderson Cancer Center, Houston.
About ASTRO: ASTRO is the premier radiation oncology society in the world, with nearly 11,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy.
About Genprex: Genprex Inc. is a biopharmaceutical company founded to bridge critical gaps in the cancer therapeutics sector by developing products to unlock the potential of proven but limited cancer drugs. The Company is working to expand clinical populations benefitting from targeted, small molecule therapies by using its biologic agents to combine small molecule drugs to promote genome-wide applications of the combination therapy and to participate in expanding proven markets. The Company’s biologics are designed to program cells to overcome intrinsic and acquired small molecule drug resistance without additional toxicities and to sensitize cancer cells to small and large molecule cancer drugs. Genprex, based in Austin, Texas, works with world-class institutions and collaborators to in-license and develop drug candidates and controls 16 issued and 9 pending patents, including its Oncoprex technologies. Its discovery and R&D programs have been the subject of more than 30 peer-reviewed publications and have been supported by $50 million from investigator grant awards and corporate funding.